Yanli Ji

Dr. Yanli Ji


Research Focus & Metrics

Academic Career Length

11Years (2016-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
19 September 2022 in Vox Sanguinis
Verified
Journal Article
Closed access
CGChristoph Gassner
Christoph Gassner
LCLilian Castilho
Lilian Castilho
QCQing Chen
Qing Chen
FCFrederik Banch Clausen
Frederik Banch Clausen
GDGregory A. Denomme
Gregory A. Denomme
CHCatherine A. Hyland
Catherine A. Hyland

13 January 2023 in Blood
Verified
Journal Article
Open access
PDF file
YJYanli Ji
Yanli Ji
YLYalin Luo
Yalin Luo
JWJizhi Wen
Jizhi Wen
YSYuanfan Sun
Yuanfan Sun
SJShuangshuang Jia
Shuangshuang Jia
YFYongshui Fu
Yongshui Fu
Red blood cells (RBCs) of the Asian-type DEL phenotype express few RhD proteins and are typed as serologic RhD-negative (D-) in routine testing. RhD-positive (D+) RBC transfusion for Asian-type DEL patients has been proposed but has not been generally adopted due to a lack of direct evidence regarding its safety and underlying mechanism. We performed a single-arm multicenter clinical trial to document the outcome of D+ RBC transfusion in Asian-type DEL patients; none of the recipients (0/42; 95% confidence interval, 0%-8.40%) developed alloanti-D after a median follow-up of 226 days. We conducted a large retrospective study to detect alloanti-D immunization in 4,045 serologic D- pregnant women throughout China; alloanti-D was found only in true D- individuals (2.63%, 79/3,009), but not in those with Asian-type DEL (0/1,032). We further retrospectively examined 127 serologic D- pregnant women who had developed alloanti-D and found none with Asian-type DEL (0/127). Finally, we analyzed RHD transcripts from Asian-type DEL erythroblasts and examined antigen epitopes expressed by various RHD transcripts in vitro, finding a low abundance of full-length RHD transcripts (0.18% of the total) expressing RhD antigens carrying the entire repertoire of epitopes, which could explain the immune tolerance against D+ RBCs. Our results provide multiple lines of evidence that individuals with Asian-type DEL cannot produce alloanti-D when exposed to D+ RBCs following transfusion or pregnancy. Therefore, we recommend considering D+ RBC transfusion and discontinuing anti-D prophylaxis in Asian-type DEL patients, including pregnant women. This clinical trial is registered at www.clinicaltrials.gov as NCT03727230.

6 December 2018 in Transfusion
Verified
Journal Article
Closed access
PDF file
SLSi Li
Si Li
CMChunyan Mo
Chunyan Mo
LHLinhuan Huang
Linhuan Huang
XSXiaomei Shi
Xiaomei Shi
GLGuangping Luo
Guangping Luo
QFQun Fang
Qun Fang

10 January 2022 in Vox Sanguinis
Verified
Journal Article
Open access
PDF file
YJYanli Ji
Yanli Ji
GLGuangping Luo
Guangping Luo
YFYongshui Fu
Yongshui Fu
Background and Objectives: The transfusion of D‐negative red blood cells (RBCs) to D‐negative patients has been widely adopted to prevent anti‐D alloimmunization, especially in women of childbearing age. Still, transfusion of D‐positive RBCs to D‐negative recipients is occasionally inevitable in practice, and the resulting incidence of anti‐D in different D‐negative groups of patients has not been well summarized.Materials and Methods: We searched the relevant literature using PubMed, Cochrane Library, and Embase databases from inception date to 30 September 2021. We looked for studies of anti‐D occurring in D‐negative recipients who received D‐positive RBC transfusions. The anti‐D incidence was summarized with 95% confidence intervals (CIs). Data with similar characteristics were combined using a random‐effects model.Results: About 42 studies (2226 cases), which found anti‐D, the exact volume of D‐positive RBC transfused, and the follow‐up time for anti‐D detection, met the inclusion criteria. The pooled anti‐D incidence was 64% (95% CI, range 55%–74%) in volunteers receiving small volumes of D‐positive RBCs, 84% (95% CI, 74%–94%) in those receiving whole units, 26% (95% CI, 19%–32%) in mixed patients, 12% (95% CI, 8%–16%) in oncology patients, 27% (95% CI, 13%–40%) in trauma patients, 4% (95% CI, 0%–8%) in immune‐compromised transplant patients, and 6% (95% CI, 1%–39%) in those with AIDS.Conclusion: Compared with the high frequency of anti‐D in healthy D‐negative volunteers given D‐positive RBCs, we found a lower rate of anti‐D immunization in various D‐negative patients and almost none in transplant and AIDS patients.

21 June 2021 in Vox Sanguinis
Verified
Journal Article
Open access
PDF file
FCFrederik Clausen
Frederik Clausen
ÅHÅsa Hellberg
Åsa Hellberg
GBGregor Bein
Gregor Bein
PBPeter Bugert
Peter Bugert
DSDieter Schwartz
Dieter Schwartz
TLTobias Legler
Tobias Legler
Background and Objectives: Non‐invasive assays for predicting foetal blood group status in pregnancy serve as valuable clinical tools in the management of pregnancies at risk of detrimental consequences due to blood group antigen incompatibility. To secure clinical applicability, assays for non‐invasive prenatal testing of foetal blood groups need to follow strict rules for validation and quality assurance. Here, we present a multi‐national position paper with specific recommendations for validation and quality assurance for such assays and discuss their risk classification according to EU regulations.Materials and Methods: We reviewed the literature covering validation for in‐vitro diagnostic (IVD) assays in general and for non‐invasive foetal RHD genotyping in particular. Recommendations were based on the result of discussions between co‐authors.Results: In relation to Annex VIII of the In‐Vitro‐Diagnostic Medical Device Regulation 2017/746 of the European Parliament and the Council, assays for non‐invasive prenatal testing of foetal blood groups are risk class D devices. In our opinion, screening for targeted anti‐D prophylaxis for non‐immunized RhD negative women should be placed under risk class C. To ensure high quality of non‐invasive foetal blood group assays within and beyond the European Union, we present specific recommendations for validation and quality assurance in terms of analytical detection limit, range and linearity, precision, robustness, pre‐analytics and use of controls in routine testing. With respect to immunized women, different requirements for validation and IVD risk classification are discussed.Conclusion: These recommendations should be followed to ensure appropriate assay performance and applicability for clinical use of both commercial and in‐house assays.

13 June 2018 in Transfusion
Verified
Journal Article
Closed access
PDF file
LWLing Wei
Ling Wei
GLGenghis H. Lopez
Genghis H. Lopez
YZYang Zhang
Yang Zhang
JWJizhi Wen
Jizhi Wen
ZWZhen Wang
Zhen Wang
YJYanli Ji
Yanli Ji